Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
BMC Infect Dis ; 22(1): 39, 2022 Jan 06.
Artículo en Inglés | MEDLINE | ID: mdl-34991507

RESUMEN

BACKGROUND: Inappropriate antibiotics use in lower respiratory tract infections (LRTI) is a major contributor to resistance. We aimed to design an algorithm based on clinical signs and host biomarkers to identify bacterial community-acquired pneumonia (CAP) among patients with LRTI. METHODS: Participants with LRTI were selected in a prospective cohort of febrile (≥ 38 °C) adults presenting to outpatient clinics in Dar es Salaam. Participants underwent chest X-ray, multiplex PCR for respiratory pathogens, and measurements of 13 biomarkers. We evaluated the predictive accuracy of clinical signs and biomarkers using logistic regression and classification and regression tree analysis. RESULTS: Of 110 patients with LRTI, 17 had bacterial CAP. Procalcitonin (PCT), interleukin-6 (IL-6) and soluble triggering receptor expressed by myeloid cells-1 (sTREM-1) showed an excellent predictive accuracy to identify bacterial CAP (AUROC 0.88, 95%CI 0.78-0.98; 0.84, 0.72-0.99; 0.83, 0.74-0.92, respectively). Combining respiratory rate with PCT or IL-6 significantly improved the model compared to respiratory rate alone (p = 0.006, p = 0.033, respectively). An algorithm with respiratory rate (≥ 32/min) and PCT (≥ 0.25 µg/L) had 94% sensitivity and 82% specificity. CONCLUSIONS: PCT, IL-6 and sTREM-1 had an excellent predictive accuracy in differentiating bacterial CAP from other LRTIs. An algorithm combining respiratory rate and PCT displayed even better performance in this sub-Sahara African setting.


Asunto(s)
Neumonía Bacteriana , Infecciones del Sistema Respiratorio , Algoritmos , Biomarcadores , Proteína C-Reactiva/análisis , Humanos , Pacientes Ambulatorios , Neumonía Bacteriana/diagnóstico , Estudios Prospectivos , Infecciones del Sistema Respiratorio/diagnóstico , Tanzanía
2.
Int Arch Allergy Immunol ; 177(3): 192-198, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30130756

RESUMEN

BACKGROUND: In many rural areas of tropical countries such as Indonesia, the prevalence of soil-transmitted helminths (STH) infections remains high. At the same time, the burden of allergic disorders in such rural areas is reported to be low and inversely associated with helminth infections. To reduce the morbidity and transmission of helminth infections, the world health organization recommends preventive treatment of school children by providing mass drug administration (MDA) with albendazole. Here, we had an opportunity to evaluate the prevalence of skin reactivity to allergens before and after albendazole treatment to get an indication of the possible impact of MDA on allergic sensitization. METHODS: A study was conducted among 150 school children living in an area endemic for STH infections. Before and 1 year after anthelminthic treatment with albendazole, stool samples were examined for the presence of STH eggs, skin prick tests (SPT) for cockroach and house dust mites were performed, blood eosinophilia was assessed, and total immunoglobulin E (IgE) and C-reactive protein (CRP) were measured in plasma. RESULTS: Anthelminthic treatment significantly reduced the prevalence of STH from 19.6 before treatment to 6% after treatment (p < 0.001). Levels of total IgE (estimate: 0.30; 95% CI 0.22-0.42, p < 0.0001), CRP (estimate: 0.60; 95% CI 0.42-0.86, p = 0.006), and eosinophil counts (estimate: 0.70; 95% CI 0.61-0.80, p < 0.001) decreased significantly. The prevalence of SPT positivity increased from 18.7 to 32.7%. Multivariate analysis adjusted for confounding factors showed an increased risk of being SPT positive to any allergen (OR 3.04; 95% CI 1.338-6.919, p = 0.008). CONCLUSIONS: This study indicates that 1 year of MDA with albendazole was associated with a reduced prevalence of STH infections. This study shows that the prevalence of allergic sensitization increases after 1 year of albendazole treatment. Placebo-controlled and larger studies are needed to further substantiate a role of deworming treatment in an increased risk of allergic sensitization.


Asunto(s)
Ancylostomatoidea/inmunología , Anticuerpos Antihelmínticos/sangre , Ascaris lumbricoides/inmunología , Helmintiasis/epidemiología , Hipersensibilidad Inmediata/epidemiología , Inmunoglobulina E/sangre , Trichuris/inmunología , Albendazol/administración & dosificación , Albendazol/uso terapéutico , Alérgenos/inmunología , Animales , Antihelmínticos/administración & dosificación , Antihelmínticos/uso terapéutico , Anticuerpos Antihelmínticos/inmunología , Antígenos Helmínticos/inmunología , Proteína C-Reactiva/análisis , Niño , Cucarachas/inmunología , Femenino , Helmintiasis/tratamiento farmacológico , Helmintiasis/parasitología , Humanos , Hipersensibilidad Inmediata/sangre , Hipersensibilidad Inmediata/inmunología , Inmunoglobulina E/inmunología , Indonesia/epidemiología , Masculino , Administración Masiva de Medicamentos , Pyroglyphidae/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA